Renaissance Technologies LLC recently announced the acquisition of new stake in Plus Therapeutics Inc. (NASDAQ:PSTV). The institutional investor has increased its shareholding in the Healthcare company by 3.58% to 83949.0 shares with purchase of 2900.0 shares. This fresh investment now brings its stake to 2.04% valued currently at $0.2 million. In addition, The Vanguard Group, Inc. raised its holdings by 15281.0 to 15281.0 shares.
With over 9.72 million Plus Therapeutics Inc. (PSTV) shares trading Tuesday and a closing price of $2.83 on the day, the dollar volume was approximately $27.49 million. The shares have shown a positive weekly performance of 15.51% and its price on 09/01/20 gained nearly 15.51%. Currently, there are 4.05M common shares owned by the public and among those 3.98M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for PSTV have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $5.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Plus Therapeutics Inc. stock is 2.00 for the next 12 months. But an upside of 43.4% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 32,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Plus Therapeutics Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and USAA Extended Market Index Fund. Vanguard Extended Market Index Fu owns 15281.0 shares of the company’s stock, all valued at over $37133.0. USAA Extended Market Index Fund bought 3.0 shares to bring its total holdings to over 650.0 shares at a value of $1580.0. USAA Extended Market Index Fund now owns shares totaling to 0.02% of the shares outstanding.
Shares of Plus Therapeutics Inc. (NASDAQ: PSTV) opened at $2.91, up $0.46 from a prior closing price of $2.45. However, the script later closed the day at $2.83, up 15.51%. The company’s stock has a 5-day price change of 15.51% and 66.47% over the past three months. PSTV shares are trading 17.92% year to date (YTD), with the 12-month market performance down to -78.82% lower. It has a 12-month low price of $0.93 and touched a high of $16.00 over the same period. Currently, 9.72 million shares have been traded, compared to an average intraday trading volume of 432.83K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.35%, 13.98%, and 34.71% respectively.
Institutional ownership of Plus Therapeutics Inc. (NASDAQ: PSTV) shares accounts for 10.40% of the company’s 4.05M shares outstanding. Mutual fund holders own 0.54%, while other institutional holders and individual stakeholders account for 5.79% and 0.54% respectively.
It has a market capitalization of $12.06M and a beta (3y monthly) value of 0.53. The earnings-per-share (ttm) stands at -$0.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.25% over the week and 10.81% over the month.
Analysts forecast that Plus Therapeutics Inc. (PSTV) will achieve an EPS of -$0.65 for the current quarter, -$0.65 for the next quarter and -$2.7 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.65 while analysts give the company a high EPS estimate of -$0.65. Comparatively, EPS for the current quarter was -$0.03 a year ago. Earnings per share for the fiscal year are expected to increase by 96.80%, and -7.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Plus Therapeutics Inc. (PSTV) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”